Cargando…

A72 GASTROPARESIS: CLINICAL CHARACTERISTICS, ETIOLOGIES & RESPONSE TO TREATMENT

BACKGROUND: Gastroparesis is a gastrointestinal motor disorder characterized by a delay in gastric emptying without evidence of mechanical obstruction. Data pertaining to the demographic and clinical characteristics of gastroparesis in the Canadian population is sparse. AIMS: To review the authors’...

Descripción completa

Detalles Bibliográficos
Autores principales:	Letellier, A, Rolland, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Poster of Distinction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859240/ http://dx.doi.org/10.1093/jcag/gwab049.071

Ejemplares similares

A16 ESOPHAGEAL ORGANOID PROLIFERATION AND DIFFERENTIATION ARE ALTERED BY LOSS OF MSH2
por: Rolland, M, et al.
Publicado: (2022)

A28 RESPONSE RATE OF VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PATIENTS TO ANTI-TNF TREATMENT IS HIGHER THAN PREVIOUSLY REPORTED, BUT HIGHER DOSING IS REQUIRED-A LARGE TERTIARY SINGLE CENTER EXPERIENCE
por: Eindor, A, et al.
Publicado: (2022)

A234 IN VITRO GUT MICROBIOME AND METABOLITE RESPONSES TO RESISTANT STARCH ARE INDIVIDUALIZED
por: Dobranowski, P, et al.
Publicado: (2022)

A56 TUFT CELL RESPONSES DURING ACUTE- AND LATE-STAGE GIARDIA INFECTION
por: Sosnowski, O, et al.
Publicado: (2022)

A119 ACUTE DIVERTICULITIS & CONCURRENT DIVERTICULAR BLEED: A RARE CLINICAL ENTITY
por: Hasan, S, et al.
Publicado: (2022)

A47 MICROBIAL FUNCTIONS AS BIOMARKERS OF PRO-INFLAMMATORY RESPONSE TO SELECT DIETARY FIBERS IN IBD
por: Armstrong, H, et al.
Publicado: (2022)

A22 USING INTESTINAL ORGANOIDS TO CHARACTERIZE THE NAIP-NLRC4 INFLAMMASOME RESPONSE IN THE INTESTINAL EPITHELIUM
por: Ranger, A, et al.
Publicado: (2023)

A163 EVALUATING THE ASSOCIATION BETWEEN PERIPHERAL BLOOD EOSINOPHILS AND DRUG RESPONSE IN CROHN’S DISEASE: A PRELIMINARY REPORT
por: Cai, B, et al.
Publicado: (2022)

A24 GENERALIZABILITY OF CROHN’S DISEASE RANDOMIZED CONTROLLED TRIALS COMPARED TO CLINICAL PRACTICE
por: Chhibba, T, et al.
Publicado: (2022)

A141 IS SURGERY STILL THE ONLY TREATMENT OPTION FOR CURABLE RECTAL CANCER?
por: Vuong, T, et al.
Publicado: (2022)

A160 MOLECULAR ANALYSIS OF THE INJURY-REPAIR RESPONSE IN ULCERATIVE COLITIS REVEALS HETEROGENEITY IN DISEASE ACTIVIT
por: Madill-Thomsen, K, et al.
Publicado: (2022)

A42 HETEROGENEITY IN EFFICACY AND SAFETY ENDPOINTS FOR PEDIATRIC CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE: A NEED FOR HARMONIZATION
por: Crowley, E, et al.
Publicado: (2022)

A257 PANCREATIC CANCER TREATMENT AND END OF LIFE OUTCOMES: A POPULATION BASED COHORT STUDY
por: Khan, R, et al.
Publicado: (2022)

A154 COMPARING RESPONSE TO INTRAVENOUS IRON INFUSION IN CROHN’S DISEASE AND ULCERATIVE COLITIS
por: Su, S, et al.
Publicado: (2022)

A44 A 1000 PATIENT CANADIAN NETWORK FOR AUTOIMMUNE LIVER DISEASE EVALUATION OF CLINICAL AND DEMOGRAPHIC PATTERNS OF AUTOIMMUNE HEPATITIS
por: Plagiannakos, C G, et al.
Publicado: (2023)

A25 CRITICAL APPRAISAL OF GI ENDOSCOPY CLINICAL PRACTICE GUIDELINES DURING THE COVID-19 PANDEMIC
por: Tham, D, et al.
Publicado: (2022)

A218 THE RISK OF RECURRENT HEPATOCELLULAR CARDINOMA IN POST-LIVER TRANSPLANT PATIENTS RECEIVING CAPECITABINE TREATMENT
por: Alsager, M, et al.
Publicado: (2022)

A217 TREATMENT ADHERENCE OF CHRONIC HEPATITIS B PATIENTS WITH HEPATOCELLULAR CARCINOMA FROM THE CANHEPB NETWORK
por: Rahman, S H, et al.
Publicado: (2022)

A96 RAPID IMPLEMENTATION OF AN EVIDENCE-BASED, VIRTUAL COVID-19 VACCINE EDUCATION CLINIC AT NOVA SCOTIA COLLABORATIVE INFLAMMATORY DISEASE CLINIC (NSCIBD)
por: Komeylian, H, et al.
Publicado: (2022)

A85 THE CLINICAL IMPACT OF COVID-19 DELAYS ON PLASTIC BILIARY STENT REMOVAL IN NOVA SCOTIA
por: Lim, D R, et al.
Publicado: (2021)

A50 THE EFFECTS OF SHORT-CHAIN FATTY ACIDS ON EPITHELIAL AND MACROPHAGE RESPONSE TO BACTEROIDES FRAGILIS
por: Bording-Jorgensen, M, et al.
Publicado: (2023)

A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Wetwittayakhlang, P, et al.
Publicado: (2022)

A32 PHAGE TREATMENT DELAYS ONSET OF CROHN’S-ASSOCIATED E. COLI DRIVEN COLITIS IN MICE COLONIZED WITH A DEFINED MICROBIOTA
por: Jackson, K, et al.
Publicado: (2023)

A129 CYP2C19 PHARMACOGENETIC TESTING IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS INFLUENCES DOSING OF PROTON-PUMP-INHIBITORS AND RESPONSE TO THERAPY
por: Bortolin, K A, et al.
Publicado: (2022)

A61 PRE-ALLOGENIC STEM CELL TRANSPLANT CLINICAL FACTORS AND THEIR ASSOCIATION WITH CHRONIC GRAFT VERSUS HOST DISEASE - A RISK FACTOR ANALYSIS FOR CHRONIC GVHD PREDICTION
por: Alajmi, A, et al.
Publicado: (2022)

A224 COVID-19 INFECTION IN LIVER TRANSPLANT RECIPIENTS: CLINICAL FEATURES, HOSPITALIZATION, AND MORTALITY FROM A CANADIAN MULTICENTRE COHORT
por: Smith, M K, et al.
Publicado: (2022)

A188 FACTORS ASSOCIATED WITH CLINICAL REMISSION IN PEDIATRIC LUMINAL CROHN’S DISEASE: A RETROSPECTIVE COHORT STUDY
por: Sassine, S, et al.
Publicado: (2022)

A187 RISK FACTORS OF CLINICAL RELAPSES IN PEDIATRIC LUMINAL CROHN’S DISEASE, A RETROSPECTIVE COHORT STUDY
por: Sassine, S, et al.
Publicado: (2022)

A214 SIMPLIFICATION OF CARE FOR HCV IS EFFECTIVE DURING THE COVID PANDEMIC: A RETROSPECTIVE STUDY OF HCV TREATMENT UTILIZING THE BRITISH COLUMBIA HEPATITIS C NETWORK
por: Jiang, S X, et al.
Publicado: (2022)

A186 CHANGES IN THE CLINICAL PHENOTYPE AND BEHAVIOR OF PEDIATRIC LUMINAL CROHN’S DISEASE AT DIAGNOSIS IN THE LAST DECADE
por: Sassine, S, et al.
Publicado: (2022)

A101 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM OCCURRING POST-LIVER TRANSPLANT FOR PSC WITH CLINICAL REMISSION OF ULCERATIVE COLITIS AFTER STEM CELL TRANSPLANTATION
por: Donaldson, M A, et al.
Publicado: (2022)

A33 ENDOSCOPIC ULTRASOUND-GUIDED GASTROJEJUNOSTOMY VERSUS SURGICAL GASTROJEJUNOSTOMY AND ENTERAL STENTING FOR THE TREATMENT OF MALIGNANT GASTRIC OUTLET OBSTRUCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Benchaya, J, et al.
Publicado: (2022)

A66 THE IMPACT OF A MULTIDISCIPLINARY ADOLESCENT AND YOUNG ADULT (AYA) INFLAMMATORY BOWEL DISEASE (IBD) ON CLINIC NO SHOW RATES
por: Sharma, R, et al.
Publicado: (2022)

A227 THE EFFECTIVENESS OF PEG 3350 COMPARED TO LACTULOSE FOR THE TREATMENT OF ACUTE HEPATIC ENCEPHALOPATHY IN ADULT CIRRHOTIC PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Afzaal, T, et al.
Publicado: (2022)

A128 PATIENT CHARACTERIZATION AND ASSESSMENT OF REMISSION RATES IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS AFTER INITIAL TREATMENT AND 1-YEAR POST-DIAGNOSIS
por: Da Silva, S, et al.
Publicado: (2022)

A45 INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR IS ASSOCIATED WITH AN ATTENUATED ANTIBODY RESPONSE TO BNT162B2 SARS-COV-2 VACCINE IN PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS
por: Lawrence, S, et al.
Publicado: (2022)

A79 AIMING TO PROVIDE EARLIER CARE WHILE REDUCING SPECIALTY CLINIC WAIT TIMES: DEVELOPING A RELIABLE PROCESS OF ASSESSING THE ELIGIBILITY OF GASTROENTEROLOGY REFERRALS FOR PRIMARY CARE PATHWAYS
por: Budhram, D, et al.
Publicado: (2022)

A108 A RETROSPECTIVE REVIEW OF COMPLEX POLYP MANAGEMENT IN THE CHAMPLAIN REGION, ONTARIO
por: Monod, A, et al.
Publicado: (2022)

A189 INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS POST RENAL TRANSPLANT:A CASE SERIES
por: Sethuraman, A, et al.
Publicado: (2022)

A197 ACUTE ILEITIS IN ADULT PATIENT: A RETROSPECTIVE STUDY OF PATIENT OUTCOMES
por: Bachand, M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m8ebebr2d32bojk2tn2o7rg00d